Blueprint Medicines Corp Stock Revenue
BPMC Stock | USD 92.26 0.03 0.03% |
Blueprint Medicines Corp fundamentals help investors to digest information that contributes to Blueprint Medicines' financial success or failures. It also enables traders to predict the movement of Blueprint Stock. The fundamental analysis module provides a way to measure Blueprint Medicines' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Blueprint Medicines stock.
Last Reported | Projected for Next Year | ||
Total Revenue | 249.4 M | 175.9 M |
Blueprint | Revenue |
Blueprint Medicines Corp Company Revenue Analysis
Blueprint Medicines' Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Current Blueprint Medicines Revenue | 249.38 M |
Most of Blueprint Medicines' fundamental indicators, such as Revenue, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Blueprint Medicines Corp is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Historical and Projected quarterly revenue of Blueprint
Projected quarterly revenue analysis of Blueprint Medicines Corp provides investors and stakeholders with an insight into the company's performance and growth prospects. When actual revenues of Blueprint Medicines match or exceed analyst estimates, it positively influences investor confidence and market perception, often leading to a rise in Blueprint Medicines' stock price.
Blueprint Revenue Driver Correlations
Understanding the fundamental principles of building solid financial models for Blueprint Medicines is extremely important. It helps to project a fair market value of Blueprint Stock properly, considering its historical fundamentals such as Revenue. Since Blueprint Medicines' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Blueprint Medicines' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Blueprint Medicines' interrelated accounts and indicators.
0.14 | -0.17 | 0.19 | 0.1 | 0.2 | ||
0.14 | -0.27 | 0.29 | 0.99 | 0.81 | ||
-0.17 | -0.27 | 0.06 | -0.27 | -0.54 | ||
0.19 | 0.29 | 0.06 | 0.29 | 0.44 | ||
0.1 | 0.99 | -0.27 | 0.29 | 0.8 | ||
0.2 | 0.81 | -0.54 | 0.44 | 0.8 |
Click cells to compare fundamentals
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
Competition |
Blueprint Current Deferred Revenue
Current Deferred Revenue |
|
Based on the latest financial disclosure, Blueprint Medicines Corp reported 249.38 M of revenue. This is 96.73% lower than that of the Biotechnology sector and 66.43% lower than that of the Health Care industry. The revenue for all United States stocks is 97.36% higher than that of the company.
Blueprint Revenue Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Blueprint Medicines' direct or indirect competition against its Revenue to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Blueprint Medicines could also be used in its relative valuation, which is a method of valuing Blueprint Medicines by comparing valuation metrics of similar companies.Blueprint Medicines is currently under evaluation in revenue category among related companies.
Blueprint Medicines Institutional Holders
Institutional Holdings refers to the ownership stake in Blueprint Medicines that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Blueprint Medicines' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Blueprint Medicines' value.Shares | Jpmorgan Chase & Co | 2023-12-31 | 1.5 M | Lord, Abbett & Co Llc | 2023-12-31 | 1.4 M | Alliancebernstein L.p. | 2023-12-31 | 1.4 M | Geode Capital Management, Llc | 2023-12-31 | 1.3 M | Morgan Stanley - Brokerage Accounts | 2023-12-31 | 1.2 M | Goldman Sachs Group Inc | 2023-12-31 | 1.2 M | Polar Capital Holdings Plc | 2023-12-31 | 865 K | Woodline Partners Lp | 2023-12-31 | 814.5 K | American Century Companies Inc | 2023-12-31 | 711.7 K | Blackrock Inc | 2023-12-31 | 6.6 M | Vanguard Group Inc | 2023-12-31 | 6.1 M |
Blueprint Fundamentals
Return On Equity | -1.57 | ||||
Return On Asset | -0.25 | ||||
Profit Margin | (2.03) % | ||||
Operating Margin | (1.46) % | ||||
Current Valuation | 5.71 B | ||||
Shares Outstanding | 61.23 M | ||||
Shares Owned By Insiders | 0.85 % | ||||
Shares Owned By Institutions | 99.15 % | ||||
Number Of Shares Shorted | 4.37 M | ||||
Price To Earning | 7.93 X | ||||
Price To Book | 40.90 X | ||||
Price To Sales | 21.42 X | ||||
Revenue | 249.38 M | ||||
Gross Profit | 177.28 M | ||||
EBITDA | (474.61 M) | ||||
Net Income | (506.98 M) | ||||
Cash And Equivalents | 853.11 M | ||||
Cash Per Share | 14.28 X | ||||
Total Debt | 774.12 M | ||||
Debt To Equity | 0.14 % | ||||
Current Ratio | 6.00 X | ||||
Book Value Per Share | 2.14 X | ||||
Cash Flow From Operations | (436.85 M) | ||||
Short Ratio | 5.37 X | ||||
Earnings Per Share | (8.37) X | ||||
Target Price | 97.38 | ||||
Number Of Employees | 655 | ||||
Beta | 0.65 | ||||
Market Capitalization | 5.61 B | ||||
Total Asset | 1.05 B | ||||
Retained Earnings | (2.34 B) | ||||
Working Capital | 593.47 M | ||||
Current Asset | 170.42 M | ||||
Current Liabilities | 18.64 M | ||||
Net Asset | 1.05 B |
About Blueprint Medicines Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Blueprint Medicines Corp's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Blueprint Medicines using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Blueprint Medicines Corp based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Blueprint Medicines Investors Sentiment
The influence of Blueprint Medicines' investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Blueprint. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to Blueprint Medicines' public news can be used to forecast risks associated with an investment in Blueprint. The trend in average sentiment can be used to explain how an investor holding Blueprint can time the market purely based on public headlines and social activities around Blueprint Medicines Corp. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Blueprint Medicines' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Blueprint Medicines' and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Blueprint Medicines' news discussions. The higher the estimated score, the more favorable is the investor's outlook on Blueprint Medicines.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Blueprint Medicines in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Blueprint Medicines' short interest history, or implied volatility extrapolated from Blueprint Medicines options trading.
Pair Trading with Blueprint Medicines
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Blueprint Medicines position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Blueprint Medicines will appreciate offsetting losses from the drop in the long position's value.Moving together with Blueprint Stock
0.79 | VKTX | Viking Therapeutics Potential Growth | PairCorr |
0.67 | ELEV | Elevation Oncology Earnings Call This Week | PairCorr |
Moving against Blueprint Stock
0.43 | GILD | Gilead Sciences Earnings Call Today | PairCorr |
The ability to find closely correlated positions to Blueprint Medicines could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Blueprint Medicines when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Blueprint Medicines - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Blueprint Medicines Corp to buy it.
The correlation of Blueprint Medicines is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Blueprint Medicines moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Blueprint Medicines Corp moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Blueprint Medicines can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Blueprint Medicines Piotroski F Score and Blueprint Medicines Altman Z Score analysis. You can also try the Economic Indicators module to top statistical indicators that provide insights into how an economy is performing.
Complementary Tools for Blueprint Stock analysis
When running Blueprint Medicines' price analysis, check to measure Blueprint Medicines' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Blueprint Medicines is operating at the current time. Most of Blueprint Medicines' value examination focuses on studying past and present price action to predict the probability of Blueprint Medicines' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Blueprint Medicines' price. Additionally, you may evaluate how the addition of Blueprint Medicines to your portfolios can decrease your overall portfolio volatility.
Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
Economic Indicators Top statistical indicators that provide insights into how an economy is performing |
Is Blueprint Medicines' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Blueprint Medicines. If investors know Blueprint will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Blueprint Medicines listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (8.37) | Revenue Per Share 4.118 | Quarterly Revenue Growth 0.855 | Return On Assets (0.25) | Return On Equity (1.57) |
The market value of Blueprint Medicines Corp is measured differently than its book value, which is the value of Blueprint that is recorded on the company's balance sheet. Investors also form their own opinion of Blueprint Medicines' value that differs from its market value or its book value, called intrinsic value, which is Blueprint Medicines' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Blueprint Medicines' market value can be influenced by many factors that don't directly affect Blueprint Medicines' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Blueprint Medicines' value and its price as these two are different measures arrived at by different means. Investors typically determine if Blueprint Medicines is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Blueprint Medicines' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.